We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Aravive Inc (ARAV) USD0.0001

Sell:$0.99 Buy:$1.01 Change: $0.04 (3.85%)
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
Sell:$0.99
Buy:$1.01
Change: $0.04 (3.85%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
Sell:$0.99
Buy:$1.01
Change: $0.04 (3.85%)
Market closed |  Prices as at close on 27 June 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The Company is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.

Contact details

Address:
RIVER OAKS TOWER
3730 KIRBY DRIVE, SUITE 1200
HOUSTON
77098
United States
Telephone:
+1 (936) 3551910
Website:
https://aravive.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARAV
ISIN:
US03890D1081
Market cap:
$29.98 million
Shares in issue:
28.83 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Fredric Eshelman
    Executive Chairman of the Board
  • Gail McIntyre
    President, Chief Executive Officer, Director
  • Rudy Howard
    Chief Financial Officer
  • Leonard Dove
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.